Cargando…

WT1 epitope-specific IgG and IgM antibodies for immune-monitoring in patients with advanced sarcoma treated with a WT1 peptide cancer vaccine

The Wilms' tumor gene WT1 is highly expressed in various malignancies and may be a common target antigen for cancer immunotherapy. In our group, peptide-based cancer vaccines targeting WT1 CTL epitopes were developed as an immunotherapy for these malignancies. In the present study, WT1 epitope-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alzaaqi, Shouq, Naka, Norifumi, Hamada, Kenichiro, Hosen, Naoki, Kanegae, Mizuki, Outani, Hidetatsu, Adachi, Mayuko, Imanishi, Rin, Morii, Eiichi, Iwai, Miki, Nakata, Jun, Fujiki, Fumihiro, Morimoto, Soyoko, Nakajima, Hiroko, Nishida, Sumiyuki, Tsuboi, Akihiro, Oka, Yoshihiro, Sugiyama, Haruo, Oji, Yusuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756391/ https://www.ncbi.nlm.nih.gov/pubmed/35069874 http://dx.doi.org/10.3892/ol.2022.13184

Ejemplares similares

Serum WT1-271 IgM antibody as a novel diagnostic marker for Gastric Cancer
por: Ito, Masaaki, et al.
Publicado: (2022)

Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide
por: Oji, Yusuke, et al.
Publicado: (2016)

WT1 Trio Peptide-Based Cancer Vaccine for Rare Cancers Expressing Shared Target WT1
por: Oji, Yusuke, et al.
Publicado: (2023)

Cellular and Humoral Immune Responses Induced by an HLA Class I–restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer
por: Nishida, Sumiyuki, et al.
Publicado: (2022)

Identification of a Novel C-Terminal Truncated WT1 Isoform with Antagonistic Effects against Major WT1 Isoforms
por: Tatsumi, Naoya, et al.
Publicado: (2015)

Extremely strong infiltration of WT1-specific CTLs into mouse tumor by the combination vaccine with WT1-specific CTL and helper peptides
por: Nakata, Jun, et al.
Publicado: (2018)

WT1 Peptide Cancer Vaccine for Patients with Hematopoietic Malignancies and Solid Cancers
por: Oka, Yoshihiro, et al.
Publicado: (2007)

Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine
por: Takashima, Satoshi, et al.
Publicado: (2016)

A phase I clinical study of a cocktail vaccine of Wilms’ tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma
por: Tsuboi, Akihiro, et al.
Publicado: (2018)

Enhanced immune reaction resulting from co-vaccination of WT1 helper peptide assessed on PET-CT
por: Nakata, Jun, et al.
Publicado: (2020)

An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia
por: Nakagawa, Natsuki, et al.
Publicado: (2022)

Prognostic significance of specific anti-WT1 IgG antibody level in plasma in patients with ovarian carcinoma
por: Andersson, Charlotta, et al.
Publicado: (2014)

Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia
por: Minagawa, Hikaru, et al.
Publicado: (2023)

Wilms Tumor Gene (WT1) Peptide–based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer
por: Nishida, Sumiyuki, et al.
Publicado: (2014)

An Immunocompetent Mouse Model for MLL/AF9 Leukemia Reveals the Potential of Spontaneous Cytotoxic T-Cell Response to an Antigen Expressed in Leukemia Cells
por: Hasegawa, Kana, et al.
Publicado: (2015)

Establishment of a novel platform cell line for efficient and precise evaluation of T cell receptor functional avidity
por: Morimoto, Soyoko, et al.
Publicado: (2018)

Immune adjuvant therapy using Bacillus Calmette–Guérin cell wall skeleton (BCG-CWS) in advanced malignancies: A phase 1 study of safety and immunogenicity assessments
por: Nishida, Sumiyuki, et al.
Publicado: (2019)

Encouraging Clinical Evolution of a Pediatric Patient With Relapsed Diffuse Midline Glioma Who Underwent WT1-Targeting Immunotherapy: A Case Report and Literature Review
por: Hashii, Yoshiko, et al.
Publicado: (2020)

Expression of the Wilms' Tumor Gene WT1 in Solid Tumors and Its Involvement in Tumor Cell Growth
por: Oji, Yusuke, et al.
Publicado: (1999)

T Cell-Intrinsic Vitamin A Metabolism and Its Signaling Are Targets for Memory T Cell-Based Cancer Immunotherapy
por: Fujiki, Fumihiro, et al.
Publicado: (2022)

Establishment of a novel NFAT-GFP reporter platform useful for the functional avidity maturation of HLA class II-restricted TCRs
por: Fujiki, Fumihiro, et al.
Publicado: (2023)

WT1 peptide analogue WT1-126Y enhances leukemia lysis
por: Alqudaihi, Ghofran, et al.
Publicado: (2014)

Isolating $Wt$ production at the LHC
por: White, Chris D., et al.
Publicado: (2009)

WT1-AS promotes cell apoptosis in hepatocellular carcinoma through down-regulating of WT1
por: Lv, Long, et al.
Publicado: (2015)

Fabrication and wear behaviour of Mg-3wt.%Al-x wt. % SiC composites
por: Jayasathyakawin, S., et al.
Publicado: (2023)

Glycosylation Status of CD43 Protein Is Associated with Resistance of Leukemia Cells to CTL-Mediated Cytolysis
por: Hasegawa, Kana, et al.
Publicado: (2016)

IMT-07 CLINICAL TRIAL OF A COCKTAIL WILMS’ TUMOR 1 (WT1) VACCINATION USING TWO HLA CLASS I PEPTIDES AND ONE CLASS II PEPTIDE FOR RECURRENT MALIGNANT GLIOMAS
por: Kagawa, Naoki, et al.
Publicado: (2019)

Imaging Assessment of Tumor Response in the Era of Immunotherapy
por: Nakata, Jun, et al.
Publicado: (2021)

IgM nephropathy revisited
por: Mubarak, Muhammed, et al.
Publicado: (2012)

IgM’s exit route
por: Reversat, Anne, et al.
Publicado: (2018)

DETECTION OF MEASLES IgM
por: Lievens, Alan W, et al.
Publicado: (1984)

Microstructure and Hot Deformation Behavior of the Mg–8 wt.% Sn–1.5 wt.% Al Alloy
por: Sun, Zhaoqian, et al.
Publicado: (2021)

Serum IgA, IgM, and IgG responses in COVID-19
por: Ma, Huan, et al.
Publicado: (2020)

Helper T cells reacting to idiotype on IgG but not IgM
Publicado: (1985)

3D Structures of IgA, IgM, and Components
por: Pan, Shunli, et al.
Publicado: (2021)

Editorial: WT1 in Development and Disease
por: Chau, You-Ying, et al.
Publicado: (2022)

Long term efficacy of WT1 peptide vaccine in patients with WT1 overexpressing hematopoeitic and solid malignancies
por: Letsch, Anne, et al.
Publicado: (2013)

Phase 1/2 study of the WT1 peptide cancer vaccine WT4869 in patients with myelodysplastic syndrome
por: Ueda, Yasunori, et al.
Publicado: (2017)

Co-Precipitation, Strength and Electrical Resistivity of Cu–26 wt % Ag–0.1 wt % Fe Alloy
por: Li, Rui, et al.
Publicado: (2017)

IgM monoclonal gammopathy of undetermined significance: clinicopathologic features with and without IgM-related disorders
por: Bruehl, Frido K., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_j7ccamn79ppk4k86nmr36vupgr